Dr Andrew Guise joins to support companies, private equity, and investors maximising value by executing strategically sound M&A and Fundraising transactions.
London, UK, 29 March 2023: PharmaVentures is pleased to announce the appointment of Andrew Guise as a Managing Director to its corporate advisory team.
Andrew is a highly accomplished executive with over 30 years of experience in finance, business development, and leadership. At UBS, he worked on over $4bn of transactions, before moving into Biotech Management, and then Venture Capital for East Hill Capital. He floated ThromboGenics in Belgium as CBO/CFO and was latterly CEO of Purity Health. He has led projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
“I am honoured to join PharmaVentures,” said Dr Guise “We are seeing a shift from financing and capital raises towards M&A, as CEOs and investors seek alternative strategies for success. Unlocking these deals and maximising value requires deeper technical expertise, long standing relationships, and the ability to invest time in seeking out options. This is where PharmaVentures excels.”
Dr Fintan Walton, Founder and CEO of PharmaVentures, said, “We are delighted to welcome Andrew to PharmaVentures. He has over 30 years’ experience in all areas of healthcare including general strategy, fundraising, innovation, exit strategy and M&A.”
Andrew has held Board/C suite roles in a number of public and private life science companies across multiple sectors. If you would like to learn more, contact Dr Guise at andrewg@pharmaventures.com
Andrew Guise joins PharmaVentures
– Ends –
For further information, please contact:
Lisa Holloway
Senior Marketing Manager
lisa@pharmaventures.com
Phone: +44 (0) 1865 332700
About PharmaVentures
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.
For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include:
- M&A (divestments, mergers, acquisitions, and strategic transactions)
- Licensing (in and out licensing)
- Fundraising Support
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuations (licensing, M&A, and fundraising)
- Pricing and Market Access
PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.
NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.
For more details, visit https://www.pharmaventures.com
Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/